Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000150748 | SCV000198198 | likely pathogenic | Fabry disease | 2018-02-15 | criteria provided, single submitter | clinical testing | proposed classification - variant undergoing re-assessment, contact laboratory |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000150748 | SCV001362666 | pathogenic | Fabry disease | 2019-11-19 | criteria provided, single submitter | clinical testing | Variant summary: GLA c.386T>C (p.Leu129Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183448 control chromosomes. c.386T>C has been reported in the literature in multiple individuals affected with Fabry Disease (Whybra_2001, Sirrs_2010, Chmiel_2018, Lenders_2016). These data indicate that the variant is very likely to be associated with disease. The variant was reported to have an in vitro enzyme activity of 0% compared to wild-type (Lukas_2013). A ClinVar submission (evaluation after 2014) cites the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV000150748 | SCV002054439 | likely pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |